Video Library
Video Library
Therapeutic Management of Dyslipidaemia
In this video, Prof. Christopher Cannon provides a comprehensive overview of our infographic on the therapeutic management of dyslipidaemia. Dyslipidaemia, a key risk factor for cardiovascular diseases, is conventionally managed through therapies targeting lipoproteins such as LDL, Lp(a), IDL + VLDL through small-molecule therapeutics. Despite their effectiveness, off-target events and poor patient compliance often pose significant challenges. Hence novel therapeutics, such as small interfering RNAs, antisense oligonucleotides, and monoclonal antibodies have been developed. These advancements highlight a significant step forward in the management of dyslipidaemia. Prof. Cannon emphasizes these main points in the video, aiming to guide clinicians in optimizing lipid-lowering therapy for cardiovascular risk prevention.
Articles
Case Studies
Case Studies
August 2023
Take this short quiz to test your knowledge on the recently published debate on dyslipidemias titled “Great debate: lipid-lowering therapies should be guided by vascular imaging rather than by circulating biomarkers”.
CLICK HERE TO VIEW THE DEBATE.
Eur Heart J. 2023 Jul 1;44(25):2292-2304. doi: 10.1093/eurheartj/ehad275
Case Studies
Quiz of the month – April 2023
Take our patient case study quiz specially curated for you by our Faculty Member, Prof. Samer Ellahham.
Case Study: A 65-year-old man with a history of dyslipidemia, type 2 diabetes mellitus and systemic hypertension.
Presentation:
New onset crescendo angina x 5 days culminating
Rest pain for the past 2h
No history of other vascular events or heart attack, no TIA or stroke
Weight: 90 kg
Exam: BP 150/85 (slightly elevated), Heart Rate 80
No murmur detected
Medication:
Valsartan 160 mg daily, Aspirin 81 mg daily, Rosuvastatin 10 mg daily, Metformin 500 mg twice daily
Labs:
BMI 31kg/m2, waist circumference 101.6 cm (40 inches), (-) tobacco (quit last year – 60-pack-year history)
Normal CBC, electrolytes
Troponin: Elevated
Electrocardiogram:1-2 mm horizontal ST depression infero-lateral leads
Chest X-ray: Normal
Lipid panel:
Total cholesterol (TC) 192 mg/dL
HDL-C 46 mg/dL
Triglycerides 180 mg/dL (non-fasting)
LDL-C 110 mg/dL
Non-HDL-C 146 mg/ dL
What are the first impressions about this patient?
Case Studies
Case Study – December 2022
Our patient case study specially curated for you by our Faculty Member, Prof. Samer Ellahham on concerns about statin associated Diabetes Mellitus.
Case Study: RS is a 64-year-old Male having dyslipidemia.
Vital parameters:
BP 144/87 mm Hg
Low-density lipoprotein cholesterol (LDL-C) 112 mg/dL
High-density lipoprotein cholesterol (HDL-C) of 47 mg/dL
Triglycerides 190 mg/dL
(-) tobacco, (-) alcohol
Body mass index (BMI) 33 kg/m2
Medication:
Valsartan 80 mg/d
Family history:
Father developed type 2 diabetes mellitus (T2DM) and ASCVD at age 58
Labs:
Fasting blood glucose 103 mg/dL
HbA1C 5.8%
Serum Creatinine 1.1 mg/dL
Urinary analysis within normal limits
RS reports that he is reluctant to take statins as they cause diabetes especially with his family history.